Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 11,199 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Urogenital Diseases Clear all
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Sefaxersen (RO7434656), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Birmingham, Alabama • Glendale, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 11:01 AM EDT
Completed No phase listed Observational

Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).

NCT02173080
View directory record Official record
Conditions
Polycystic Liver Disease
Interventions
PLD-Q
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 11:01 AM EDT
Terminated Phase 3 Interventional Results available

Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation

NCT00058188
View directory record Official record
Conditions
Osteoporosis, Prostate Cancer
Interventions
cholecalciferol, calcium gluconate, zoledronic acid
Dietary Supplement · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 15, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes

NCT02513303
View directory record Official record
Conditions
Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease, ESRD, Chronic Kidney Failure, Complication of Hemodialysis, Vascular Access Complication, Arteriovenous Fistula
Interventions
Sirolimus, AV Fistula Surgery, Sirolimus-eluting Collagen Implant (SeCI)
Drug · Procedure · Device
Lead sponsor
Vascular Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Huntsville, Alabama • Phoenix, Arizona • Escondido, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 15, 2026, 11:01 AM EDT
Active, not recruiting Not applicable Interventional

A Study of a Pelvic Floor Muscle Exercise Program Before and After Radical Prostatectomy

NCT06671782
View directory record Official record
Conditions
Prostate Cancer
Interventions
Kegel exercises, Pelvic Floor Muscle Exercise Program with biofeedback, Questionnaires, Interviews
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 15, 2026, 11:01 AM EDT
Completed Not applicable Interventional

Effects of a Walking Intervention in Older Patients With Chronic Kidney Disease: Feasibility Study

NCT02155127
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
walking
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 15, 2026, 11:01 AM EDT
Recruiting Phase 1Phase 2 Interventional

PS-002 for the Treatment of IgA Nephropathy in Adults

NCT07182227
View directory record Official record
Conditions
Immunoglobulin A (IgA) Nephropathy
Interventions
PS-002
Genetic
Lead sponsor
Purespring Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 15, 2026, 11:01 AM EDT
Terminated Phase 2 Interventional Results available

Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme

NCT00837824
View directory record Official record
Conditions
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Interventions
Fabrazyme (agalsidase beta)
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
9
States / cities
Farmington, Connecticut • Coral Springs, Florida • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 15, 2026, 11:01 AM EDT
Not yet recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

NCT07593079
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest
Drug · Device · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 11:01 AM EDT
Terminated Phase 2 Interventional

A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)

NCT01094496
View directory record Official record
Conditions
Bladder Cancer
Interventions
CDX-1307 Vaccine Regimen, Chemotherapy
Biological · Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
17
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 15, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Results available

Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily

NCT00827242
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Placebo, tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Huntsville, Alabama • Middlebury, Connecticut • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2010 · Synced Oct 15, 2026, 11:01 AM EDT
Completed Phase 4 Interventional Results available

Fondaparinux in Critically Ill Patients With Renal Failure

NCT01467583
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Fondaparinux
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 15, 2026, 11:01 AM EDT
Recruiting No phase listed Observational

Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI

NCT04992728
View directory record Official record
Conditions
Prostate Cancer
Interventions
Restricted Spectrum Magnetic Resonance Imagining
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 15, 2026, 11:01 AM EDT
Completed Phase 1 Interventional

Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma

NCT00276536
View directory record Official record
Conditions
Breast Cancer, Kidney Cancer, Lymphoma, Melanoma, Multiple Myeloma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
recombinant interferon alpha-1b, IFN
Biological · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 15, 2026, 11:01 AM EDT
Completed Not applicable Interventional Results available

A Clinical Study of the Effectiveness and Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence (SUI)

NCT02131311
View directory record Official record
Conditions
Stress Urinary Incontinence (SUI)
Interventions
disposable, single-use pessary
Device
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years and older · Female only
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 15, 2026, 11:01 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors

NCT00415571
View directory record Official record
Conditions
Hypogonadism, Erectile Dysfunction
Interventions
Fispemifene (once daily for 8 weeks)
Drug
Lead sponsor
QuatRx Pharmaceuticals Company
Industry
Eligibility
20 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 15, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Results available

Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer

NCT00142506
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction
Interventions
sildenafil citrate and questionaires, placebo tablets and questionaires
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 15, 2026, 11:01 AM EDT
Recruiting Phase 2 Interventional

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

NCT05765500
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Relugolix, Leuprolide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • Foxborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 15, 2026, 11:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolic Abnormalities - HIV Infected and Uninfected Males

NCT00260936
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years · Male only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
12
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 15, 2026, 11:01 AM EDT
Recruiting Phase 2 Interventional

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

NCT04734730
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Bicalutamide, Degarelix, Goserelin Acetate, Leuprolide Acetate, Prednisone, Questionnaire Administration, Talazoparib
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 15, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Accuracy and Usability of the ACR | U.S. Urine Analysis Test System in the Lay User Hands

NCT04626271
View directory record Official record
Conditions
Albuminuria
Interventions
ACR | U.S. Urine Analysis Test System, URiSCAN Optima Urine Analyzer
Device
Lead sponsor
Healthy.io Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Garden City, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 15, 2026, 11:01 AM EDT
Recruiting Early Phase 1 Interventional

Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease

NCT07568509
View directory record Official record
Conditions
Arginine Vasopressin Deficiency, Oxytocin Deficiency, Pediatric Disease, Hypopituitarism
Interventions
Norethindrone Acetate-Ethinyl Estradiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 11:01 AM EDT
Recruiting No phase listed Observational

Characterizing the Genomic Landscape of Cancer in Native American Populations (NAT-Geno)

NCT06960798
View directory record Official record
Conditions
Prostate Cancer, Renal Cell Carcinoma (RCC)
Interventions
Bio-specimen Collection, Blood Draw
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 11:01 AM EDT
Active, not recruiting Phase 2 Interventional

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

NCT03899987
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
EC Aspirin, Radical Prostatectomy, Recombinant Interferon Alfa-2b, Rintatolimod
Drug · Procedure · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 15, 2026, 11:01 AM EDT